Neboglamine hydrochloride

Research use only, not for human use.

Neboglamine (CR-2249, XY-2401) hydrochloride, an orally active positive modulator of the NMDA receptor glycine site, can be used in schizophrenia research .

Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.

——

Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats.Animal Model:Male Wistar ratsDosage:20 mg/kg Administration: Subcutaneous injectionResult:Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group.Significantly inhibited phencyclidine-induced hypermobility.Animal Model:Male Wistar rats Dosage:0.3 mg/kg, 3 mg/kg, 30 mg/kg Administration: Oral administration Result: Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).

——

Membrane Transporter/Ion Channel

NMDAR

NMDAR

——

——

2759182-59-5

292.8

C13H25ClN2O3

>98% (HPLC)

——

N(C([C@H](CCC(O)=O)N)=O)C1CCC(C)(C)CC1.Cl

——

(-20℃)

With Ice Pack

≥ 2 years